Development of ACE2 autoantibodies after SARS-CoV-2 infection

• Published in: PloS one 2021-09, Vol.16 (9), p.e0257016
• Main Authors: Arthur, John M, Forrest, J Craig, Boehme, Karl W, Kennedy, Joshua L, Owens, Shana, Herzog, Christian, Liu, Juan, Harville, Terry O
• Format: Article
• Language: English
• Subjects: ACE2; Analysis; Angiotensin; Angiotensin converting enzyme; Angiotensin II; Angiotensin II - blood; Angiotensin II - immunology; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - genetics; Antibodies; Asymptomatic; Autoantibodies; Autoantibodies - blood; Autoantibodies - immunology; Autoantibodies - isolation & purification; Biology and Life Sciences; Complications; Coronaviruses; COVID-19; COVID-19 - blood; COVID-19 - immunology; COVID-19 - virology; Enzymatic activity; Enzyme activity; Enzymes; Female; Health aspects; Humans; Immune system; Immunology; Infections; Inflammation; Laboratories; Male; Medical research; Medicine and Health Sciences; Pathogenesis; Peptidyl-dipeptidase A; Peptidyl-Dipeptidase A - blood; Plasma; Proteins; Receptor, Angiotensin, Type 1 - blood; Receptor, Angiotensin, Type 1 - genetics; Receptor, Angiotensin, Type 1 - immunology; Renin-Angiotensin System - genetics; Renin-Angiotensin System - immunology; Research and Analysis Methods; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; SARS-CoV-2 - isolation & purification; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - blood; Spike Glycoprotein, Coronavirus - immunology; Spike Glycoprotein, Coronavirus - isolation & purification; Spike protein; Viral diseases
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0257016

Activation of the immune system is implicated in the Post-Acute Sequelae after SARS-CoV-2 infection (PASC) but the mechanisms remain unknown. Angiotensin-converting enzyme 2 (ACE2) cleaves angiotensin II (Ang II) resulting in decreased activation of the AT1 receptor and decreased immune system activation. We hypothesized that autoantibodies against ACE2 may develop after SARS-CoV-2 infection, as anti-idiotypic antibodies to anti-spike protein antibodies. We tested plasma or serum for ACE2 antibodies in 67 patients with known SARS-CoV-2 infection and 13 with no history of infection. None of the 13 patients without history of SARS-CoV-2 infection and 1 of the 20 outpatients that had a positive PCR test for SARS-CoV-2 had levels of ACE2 antibodies above the cutoff threshold. In contrast, 26/32 (81%) in the convalescent group and 14/15 (93%) of patients acutely hospitalized had detectable ACE2 antibodies. Plasma from patients with antibodies against ACE2 had less soluble ACE2 activity in plasma but similar amounts of ACE2 protein compared to patients without ACE2 antibodies. We measured the capacity of the samples to inhibit ACE2 enzyme activity. Addition of plasma from patients with ACE2 antibodies led to decreased activity of an exogenous preparation of ACE2 compared to patients that did not have antibodies. Many patients with a history of SARS-CoV-2 infection have antibodies specific for ACE2. Patients with ACE2 antibodies have lower activity of soluble ACE2 in plasma. Plasma from these patients also inhibits exogenous ACE2 activity. These findings are consistent with the hypothesis that ACE2 antibodies develop after SARS-CoV-2 infection and decrease ACE2 activity. This could lead to an increase in the abundance of Ang II, which causes a proinflammatory state that triggers symptoms of PASC.